Drug Profile
Trastuzumab biosimilar - Mabion
Alternative Names: MabionHER2Latest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator Mabion
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer